CN102333887B - 用于检测gi癌转移的方法 - Google Patents
用于检测gi癌转移的方法 Download PDFInfo
- Publication number
- CN102333887B CN102333887B CN201080009215.XA CN201080009215A CN102333887B CN 102333887 B CN102333887 B CN 102333887B CN 201080009215 A CN201080009215 A CN 201080009215A CN 102333887 B CN102333887 B CN 102333887B
- Authority
- CN
- China
- Prior art keywords
- gcc
- gusb
- sample
- cancer
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 165
- 201000011510 cancer Diseases 0.000 title claims description 148
- 238000000034 method Methods 0.000 title abstract description 140
- 206010027476 Metastases Diseases 0.000 title abstract description 3
- 230000009401 metastasis Effects 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims abstract description 109
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 93
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 76
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims abstract description 58
- 238000001514 detection method Methods 0.000 claims abstract description 54
- 238000011002 quantification Methods 0.000 claims abstract description 41
- 210000001165 lymph node Anatomy 0.000 claims abstract description 35
- 230000004083 survival effect Effects 0.000 claims abstract description 29
- 210000000664 rectum Anatomy 0.000 claims abstract description 20
- 108010060309 Glucuronidase Proteins 0.000 claims abstract description 19
- 238000011529 RT qPCR Methods 0.000 claims abstract description 19
- 238000012544 monitoring process Methods 0.000 claims abstract description 16
- 238000004393 prognosis Methods 0.000 claims abstract description 6
- 238000003762 quantitative reverse transcription PCR Methods 0.000 claims abstract 7
- 101000924488 Homo sapiens Atrial natriuretic peptide receptor 3 Proteins 0.000 claims description 679
- 102100034605 Atrial natriuretic peptide receptor 3 Human genes 0.000 claims description 677
- 239000000523 sample Substances 0.000 claims description 280
- 102100026031 Beta-glucuronidase Human genes 0.000 claims description 232
- 238000012360 testing method Methods 0.000 claims description 132
- 230000014509 gene expression Effects 0.000 claims description 130
- 210000001519 tissue Anatomy 0.000 claims description 65
- 210000000936 intestine Anatomy 0.000 claims description 48
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 42
- 210000001072 colon Anatomy 0.000 claims description 35
- 210000004369 blood Anatomy 0.000 claims description 33
- 239000008280 blood Substances 0.000 claims description 33
- 239000003153 chemical reaction reagent Substances 0.000 claims description 33
- 238000011282 treatment Methods 0.000 claims description 24
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 22
- 201000009030 Carcinoma Diseases 0.000 claims description 21
- 238000012546 transfer Methods 0.000 claims description 19
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 18
- 201000004101 esophageal cancer Diseases 0.000 claims description 18
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims description 17
- 201000000498 stomach carcinoma Diseases 0.000 claims description 16
- 102000040430 polynucleotide Human genes 0.000 claims description 15
- 108091033319 polynucleotide Proteins 0.000 claims description 15
- 239000002157 polynucleotide Substances 0.000 claims description 15
- 238000003745 diagnosis Methods 0.000 claims description 14
- 238000005259 measurement Methods 0.000 claims description 14
- 101150001754 Gusb gene Proteins 0.000 claims description 12
- 206010054184 Small intestine carcinoma Diseases 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 238000011226 adjuvant chemotherapy Methods 0.000 claims description 7
- 230000008901 benefit Effects 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- 239000012807 PCR reagent Substances 0.000 claims description 5
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 4
- 201000001275 rectum cancer Diseases 0.000 claims description 4
- 238000003149 assay kit Methods 0.000 claims description 3
- 238000001574 biopsy Methods 0.000 claims description 3
- 101000933465 Homo sapiens Beta-glucuronidase Proteins 0.000 claims 27
- 239000003814 drug Substances 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 abstract description 160
- 238000003556 assay Methods 0.000 abstract description 36
- 208000029742 colonic neoplasm Diseases 0.000 abstract description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract description 13
- 102000053187 Glucuronidase Human genes 0.000 abstract description 13
- 210000001198 duodenum Anatomy 0.000 abstract description 9
- 108010001687 Enterotoxin Receptors Proteins 0.000 abstract description 8
- 102000000820 Enterotoxin Receptors Human genes 0.000 abstract description 8
- 238000003757 reverse transcription PCR Methods 0.000 abstract description 8
- 238000005516 engineering process Methods 0.000 abstract description 3
- 210000002919 epithelial cell Anatomy 0.000 abstract description 3
- 238000013517 stratification Methods 0.000 abstract description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 109
- 238000006243 chemical reaction Methods 0.000 description 53
- 230000009977 dual effect Effects 0.000 description 47
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 44
- 102100021699 Eukaryotic translation initiation factor 3 subunit B Human genes 0.000 description 34
- 101000896557 Homo sapiens Eukaryotic translation initiation factor 3 subunit B Proteins 0.000 description 34
- 101000988834 Homo sapiens Hypoxanthine-guanine phosphoribosyltransferase Proteins 0.000 description 34
- 238000004458 analytical method Methods 0.000 description 30
- 241000239226 Scorpiones Species 0.000 description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 230000008569 process Effects 0.000 description 26
- 101710156592 Putative TATA-binding protein pB263R Proteins 0.000 description 22
- 102100040296 TATA-box-binding protein Human genes 0.000 description 22
- 101710145783 TATA-box-binding protein Proteins 0.000 description 22
- 238000003199 nucleic acid amplification method Methods 0.000 description 20
- 230000003321 amplification Effects 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 19
- 239000000463 material Substances 0.000 description 19
- 230000008859 change Effects 0.000 description 18
- 230000002068 genetic effect Effects 0.000 description 16
- 102000039446 nucleic acids Human genes 0.000 description 16
- 108020004707 nucleic acids Proteins 0.000 description 16
- 150000007523 nucleic acids Chemical class 0.000 description 16
- 230000035945 sensitivity Effects 0.000 description 16
- 101000579123 Homo sapiens Phosphoglycerate kinase 1 Proteins 0.000 description 15
- KJWZYMMLVHIVSU-IYCNHOCDSA-N PGK1 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](CCCCCCC(O)=O)C(=O)CC1=O KJWZYMMLVHIVSU-IYCNHOCDSA-N 0.000 description 15
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 14
- 210000002784 stomach Anatomy 0.000 description 14
- 108091093088 Amplicon Proteins 0.000 description 13
- 230000002441 reversible effect Effects 0.000 description 13
- 238000013461 design Methods 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- 210000000496 pancreas Anatomy 0.000 description 12
- 238000003753 real-time PCR Methods 0.000 description 12
- 238000011160 research Methods 0.000 description 12
- 230000004087 circulation Effects 0.000 description 11
- 210000000813 small intestine Anatomy 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 210000003238 esophagus Anatomy 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 230000003139 buffering effect Effects 0.000 description 9
- 238000006731 degradation reaction Methods 0.000 description 9
- 238000007710 freezing Methods 0.000 description 9
- 230000008014 freezing Effects 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 9
- 238000012545 processing Methods 0.000 description 9
- 238000010839 reverse transcription Methods 0.000 description 9
- 238000004422 calculation algorithm Methods 0.000 description 8
- 206010017758 gastric cancer Diseases 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 238000010606 normalization Methods 0.000 description 8
- 239000012188 paraffin wax Substances 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 239000011547 Bouin solution Substances 0.000 description 7
- 239000013614 RNA sample Substances 0.000 description 7
- 230000006399 behavior Effects 0.000 description 7
- 230000007062 hydrolysis Effects 0.000 description 7
- 238000006460 hydrolysis reaction Methods 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 201000011549 stomach cancer Diseases 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 238000011049 filling Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000013207 serial dilution Methods 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 101150010856 CRT gene Proteins 0.000 description 5
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- -1 GUSB Proteins 0.000 description 5
- 102100022662 Guanylyl cyclase C Human genes 0.000 description 5
- 101000899808 Homo sapiens Guanylyl cyclase C Proteins 0.000 description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 5
- 206010061289 metastatic neoplasm Diseases 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 description 5
- 241000252983 Caecum Species 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 238000005251 capillar electrophoresis Methods 0.000 description 4
- 210000004534 cecum Anatomy 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 210000003405 ileum Anatomy 0.000 description 4
- 210000001630 jejunum Anatomy 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 208000011645 metastatic carcinoma Diseases 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 230000000306 recurrent effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 description 3
- 210000001815 ascending colon Anatomy 0.000 description 3
- 210000001731 descending colon Anatomy 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000007834 ligase chain reaction Methods 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 206010038038 rectal cancer Diseases 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000001599 sigmoid colon Anatomy 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 210000003384 transverse colon Anatomy 0.000 description 3
- BMUDPLZKKRQECS-UHFFFAOYSA-K 3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid iron(3+) hydroxide Chemical compound [OH-].[Fe+3].[N-]1C2=C(C)C(CCC(O)=O)=C1C=C([N-]1)C(CCC(O)=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 BMUDPLZKKRQECS-UHFFFAOYSA-K 0.000 description 2
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101001094827 Homo sapiens Phosphomannomutase 1 Proteins 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 102100035367 Phosphomannomutase 1 Human genes 0.000 description 2
- 208000003837 Second Primary Neoplasms Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 238000005530 etching Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 201000002313 intestinal cancer Diseases 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- YDTFRJLNMPSCFM-YDALLXLXSA-M levothyroxine sodium anhydrous Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 YDTFRJLNMPSCFM-YDALLXLXSA-M 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 208000020615 rectal carcinoma Diseases 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 238000004513 sizing Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- AQQSXKSWTNWXKR-UHFFFAOYSA-N 2-(2-phenylphenanthro[9,10-d]imidazol-3-yl)acetic acid Chemical compound C1(=CC=CC=C1)C1=NC2=C(N1CC(=O)O)C1=CC=CC=C1C=1C=CC=CC=12 AQQSXKSWTNWXKR-UHFFFAOYSA-N 0.000 description 1
- 102100040881 60S acidic ribosomal protein P0 Human genes 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 101000672034 Bacillus sp. (strain GL1) Unsaturated glucuronyl hydrolase Proteins 0.000 description 1
- 102100027314 Beta-2-microglobulin Human genes 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010083123 CDX2 Transcription Factor Proteins 0.000 description 1
- 102000006277 CDX2 Transcription Factor Human genes 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- 102100028472 DNA-directed RNA polymerases I, II, and III subunit RPABC5 Human genes 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 101000673456 Homo sapiens 60S acidic ribosomal protein P0 Proteins 0.000 description 1
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 description 1
- 101000723805 Homo sapiens DNA-directed RNA polymerases I, II, and III subunit RPABC5 Proteins 0.000 description 1
- 101001067833 Homo sapiens Peptidyl-prolyl cis-trans isomerase A Proteins 0.000 description 1
- 101000662049 Homo sapiens Polyubiquitin-C Proteins 0.000 description 1
- 101000735893 Homo sapiens Proteasome subunit beta type-6 Proteins 0.000 description 1
- 101000595252 Homo sapiens Serine/threonine-protein phosphatase PP1-alpha catalytic subunit Proteins 0.000 description 1
- 101000653679 Homo sapiens Translationally-controlled tumor protein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- ZBZXYUYUUDZCNB-UHFFFAOYSA-N N-cyclohexa-1,3-dien-1-yl-N-phenyl-4-[4-(N-[4-[4-(N-[4-[4-(N-phenylanilino)phenyl]phenyl]anilino)phenyl]phenyl]anilino)phenyl]aniline Chemical compound C1=CCCC(N(C=2C=CC=CC=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)N(C=2C=CC=CC=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)N(C=2C=CC=CC=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)N(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 ZBZXYUYUUDZCNB-UHFFFAOYSA-N 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 description 1
- 102100037935 Polyubiquitin-C Human genes 0.000 description 1
- 102100036128 Proteasome subunit beta type-6 Human genes 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102100036033 Serine/threonine-protein phosphatase PP1-alpha catalytic subunit Human genes 0.000 description 1
- 240000002825 Solanum vestissimum Species 0.000 description 1
- 235000018259 Solanum vestissimum Nutrition 0.000 description 1
- 102100029887 Translationally-controlled tumor protein Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000011353 adjuvant radiotherapy Methods 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000011498 curative surgery Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 210000000188 diaphragm Anatomy 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000005014 ectopic expression Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 108010067006 heat stable toxin (E coli) Proteins 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940076522 listerine Drugs 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 238000001821 nucleic acid purification Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000000088 plastic resin Substances 0.000 description 1
- 101150038183 pmm1 gene Proteins 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 238000010880 proctocolectomy Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 208000013718 rectal benign neoplasm Diseases 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000005005 sentinel lymph node Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- ZSDSQXJSNMTJDA-UHFFFAOYSA-N trifluralin Chemical compound CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O ZSDSQXJSNMTJDA-UHFFFAOYSA-N 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15517209P | 2009-02-25 | 2009-02-25 | |
| US61/155,172 | 2009-02-25 | ||
| US24619709P | 2009-09-28 | 2009-09-28 | |
| US61/246,197 | 2009-09-28 | ||
| PCT/CA2010/000277 WO2010096929A1 (en) | 2009-02-25 | 2010-02-24 | Method for detecting metastasis of gi cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102333887A CN102333887A (zh) | 2012-01-25 |
| CN102333887B true CN102333887B (zh) | 2014-04-02 |
Family
ID=42664977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080009215.XA Expired - Fee Related CN102333887B (zh) | 2009-02-25 | 2010-02-24 | 用于检测gi癌转移的方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20110306055A1 (enExample) |
| EP (2) | EP2401394B1 (enExample) |
| JP (1) | JP2012518389A (enExample) |
| CN (1) | CN102333887B (enExample) |
| AU (1) | AU2010217160C1 (enExample) |
| CA (1) | CA2752668A1 (enExample) |
| WO (1) | WO2010096929A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011050242A1 (en) | 2009-10-23 | 2011-04-28 | Millennium Pharmaceuticals, Inc. | Anti-gcc antibody molecules and related compositions and methods |
| US9416410B2 (en) * | 2012-02-14 | 2016-08-16 | Genetics Development Corporation | Cutoff point delta Ct. method for HER2 PCR testing in breast cancer |
| EP2841575B1 (en) | 2012-04-27 | 2019-06-26 | Millennium Pharmaceuticals, Inc. | Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy |
| WO2016028141A1 (en) * | 2014-08-18 | 2016-02-25 | Universiti Kebangsaan Malaysia | Method for determining prognosis of colorectal cancer |
| AU2015319850B2 (en) | 2014-09-25 | 2019-09-26 | Bt Bidco, Inc. | Electromechanical pill device with localization capabilities |
| CA3034267A1 (en) * | 2016-08-18 | 2018-02-22 | Mitchell Lawrence Jones | Systems for obtaining samples using ingestible devices |
| US20180070857A1 (en) | 2016-09-09 | 2018-03-15 | Progenity Inc. | Electromechanical ingestible device for delivery of a dispensable substance |
| EP3551047A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| US11761032B2 (en) * | 2017-03-11 | 2023-09-19 | Yan Wang | Methods and devices for performing real time digital PCR |
| EP3900613B1 (en) | 2017-03-31 | 2023-12-27 | Biora Therapeutics, Inc. | Localization methods for an ingestible device |
| CN116726362A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| CN110819715A (zh) * | 2019-11-26 | 2020-02-21 | 华夏帮服科技有限公司 | 用于结直肠癌检测的免疫基因标志物及试剂盒 |
| CN118460719A (zh) * | 2020-03-02 | 2024-08-09 | 腾辰生物科技(上海)有限公司 | 一种分子标志物及试剂盒在辅助诊断食管癌中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008045133A2 (en) * | 2006-03-03 | 2008-04-17 | Veridex, Llc | Molecular assay to predict recurrence of dukes' b colon cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4194113B2 (ja) | 1993-10-26 | 2008-12-10 | トーマス・ジェファーソン・ユニバーシティ | 結腸直腸癌細胞に特異的に結合する組成物およびその使用方法 |
| US5601990A (en) | 1994-09-13 | 1997-02-11 | Thomas Jefferson University | Methods of diagnosing colorectal tumors and metastasis thereof |
| US6602659B1 (en) | 1996-05-03 | 2003-08-05 | Thomas Jefferson University | Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof |
| US6120995A (en) | 1997-08-07 | 2000-09-19 | Thomas Jefferson University | Compositions that specifically bind to colorectal cancer cells and methods of using the same |
| US7135333B1 (en) | 1997-08-07 | 2006-11-14 | Thomas Jefferson University | Compositions that specifically bind to colorectal cancer cells and methods of using the same |
| US6844153B2 (en) | 2000-03-27 | 2005-01-18 | Thomas Jefferson University | Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
| US7138226B2 (en) | 2002-05-10 | 2006-11-21 | The University Of Miami | Preservation of RNA and morphology in cells and tissues |
| US20040018494A1 (en) * | 2002-07-25 | 2004-01-29 | Shurtliff Roxanne N | Isothermal transcription based amplification assay for detection and quantification of guanylyl cyclase C |
| DE102004024617A1 (de) * | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
-
2010
- 2010-02-24 CA CA2752668A patent/CA2752668A1/en not_active Abandoned
- 2010-02-24 CN CN201080009215.XA patent/CN102333887B/zh not_active Expired - Fee Related
- 2010-02-24 EP EP10745780.6A patent/EP2401394B1/en not_active Not-in-force
- 2010-02-24 AU AU2010217160A patent/AU2010217160C1/en not_active Ceased
- 2010-02-24 EP EP13185224.6A patent/EP2677036A3/en not_active Withdrawn
- 2010-02-24 JP JP2011550395A patent/JP2012518389A/ja active Pending
- 2010-02-24 WO PCT/CA2010/000277 patent/WO2010096929A1/en not_active Ceased
- 2010-02-24 US US12/935,201 patent/US20110306055A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008045133A2 (en) * | 2006-03-03 | 2008-04-17 | Veridex, Llc | Molecular assay to predict recurrence of dukes' b colon cancer |
Non-Patent Citations (2)
| Title |
|---|
| Real-time reverse transcription PCR and the detection of occult disease in colorectal cancer;Stephen A. Bustin等;《Molecular Aspects of Medicine》;20060630;第27卷;正文第2.4节第1-2段、第2.5.3节第1段 * |
| Stephen A. Bustin等.Real-time reverse transcription PCR and the detection of occult disease in colorectal cancer.《Molecular Aspects of Medicine》.2006,第27卷正文第2.4节、第2.5.3节. |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010096929A1 (en) | 2010-09-02 |
| CN102333887A (zh) | 2012-01-25 |
| AU2010217160C1 (en) | 2015-07-02 |
| EP2401394A1 (en) | 2012-01-04 |
| HK1165836A1 (en) | 2012-10-12 |
| AU2010217160A1 (en) | 2011-09-22 |
| EP2401394A4 (en) | 2012-07-11 |
| US20110306055A1 (en) | 2011-12-15 |
| AU2010217160B2 (en) | 2014-11-20 |
| JP2012518389A (ja) | 2012-08-16 |
| CA2752668A1 (en) | 2010-09-02 |
| EP2401394B1 (en) | 2013-11-27 |
| EP2677036A2 (en) | 2013-12-25 |
| EP2677036A3 (en) | 2014-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102333887B (zh) | 用于检测gi癌转移的方法 | |
| Yang et al. | MicroRNAs in stool samples as potential screening biomarkers for pancreatic ductal adenocarcinoma cancer | |
| ES2741745T3 (es) | Método para usar la expresión génica para determinar el pronóstico de cáncer de próstata | |
| JP6049739B2 (ja) | 前立腺癌の分類のためのマーカー遺伝子 | |
| Rahbari et al. | Identification of differentially expressed microRNA in parathyroid tumors | |
| ES2829415T3 (es) | Algoritmo de perfil de expresión génica para calcular una puntuación de recurrencia para un paciente con cáncer de riñón | |
| JP2011526487A (ja) | 乳癌のゲノムフィンガープリント | |
| KR102546357B1 (ko) | 인간 포스포다이에스테라제 4d 변이체 7 발현에 기초한 위험 점수 | |
| KR20170045365A (ko) | 위장관췌장 신경내분비 신생물의 진단을 위한 조성물, 방법 및 키트 | |
| US20130323740A1 (en) | Direct blood assay for detection of circulating microrna in cancer patients | |
| Moynihan et al. | MicroRNA profile in stage I clear cell renal cell carcinoma predicts progression to metastatic disease | |
| Akbayır et al. | Diagnostic value of microRNAs in prostate cancer patients with prostate specific antigen (PSA) levels between 2, and 10 ng/mL | |
| CN110592223B (zh) | 一种NSCLC的诊断和预后标记物hsa_circRNA_012515的应用 | |
| WO2022023233A9 (en) | Biomarkers for diagnosing and monitoring lung cancer | |
| CN111763736B (zh) | 用于诊断甲状腺乳头状癌淋巴结转移的液体活检试剂盒 | |
| EP4317458A1 (en) | Follicular thyroid cancer-specific marker | |
| CN116121369A (zh) | 肾癌相关生物标志物及其应用和检测方法 | |
| WO2020188564A1 (en) | Prognostic and treatment methods for prostate cancer | |
| WO2019195935A1 (en) | Methods for monitoring and treating prostate cancer | |
| HK1165836B (en) | Method for detecting metastasis of gi cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140402 Termination date: 20170224 |